Literature DB >> 10669320

Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program.

R Harpaz1, B J McMahon, H S Margolis, C N Shapiro, D Havron, G Carpenter, L R Bulkow, R B Wainwright.   

Abstract

An immunization assessment and a serologic survey were conducted to evaluate the effectiveness of a hepatitis B immunization program in eliminating hepatitis B virus (HBV) transmission among Alaska Natives in a region in which HBV infection is endemic. Hepatitis B vaccine coverage was 93% among 567 children </=10 years old residing in the study villages, and catch-up vaccine coverage among 582 susceptible persons 11-30 years old was 62%. None of 271 tested children </=10 years old were chronically infected with HBV, and just 4 (1.5%) had evidence of resolved infection. In contrast, 16% of 332 persons 11-30 years old (those born before implementation of routine infant hepatitis B vaccination) were chronically infected. A hepatitis B immunization program that includes prevention of perinatal HBV infection, routine infant vaccination, and catch-up vaccination of older children and adults can eliminate new chronic HBV infections in a population with a high rate of chronic infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10669320     DOI: 10.1086/315259

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

Review 1.  Epidemiology of hepatitis B--clinical implications.

Authors:  Jacob Alexander; Kris V Kowdley
Journal:  MedGenMed       Date:  2006-04-13

2.  Trends in Prevalence of Protective Levels of Hepatitis B Surface Antibody Among Adults Aged 18-49 Years With Risk Factors for Hepatitis B Virus Infection-United States, 2003-2014.

Authors:  Hope King; Jian Xing; Hazel D Dean; Deborah Holtzman
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

Review 3.  Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.

Authors:  Ana F Brito; Mónica Mendes; Ana M Abrantes; José G Tralhão; Maria F Botelho
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

Review 4.  Hepatitis B virus epidemiology.

Authors:  Jennifer H MacLachlan; Benjamin C Cowie
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

5.  A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.

Authors:  Brenna C Simons; Philip R Spradling; Dana J T Bruden; Carolyn Zanis; Samantha Case; Tammy L Choromanski; Minjun Apodaca; Hazel D Brogdon; Gaelen Dwyer; Mary Snowball; Susan Negus; Michael G Bruce; Chihiro Morishima; Cindy Knall; Brian J McMahon
Journal:  J Infect Dis       Date:  2016-04-07       Impact factor: 5.226

Review 6.  Chronic hepatitis B virus infection and pregnancy.

Authors:  Manoj Kumar; Tarandeep Singh; Swati Sinha
Journal:  J Clin Exp Hepatol       Date:  2012-09-20

Review 7.  Hepatitis B (prevention).

Authors:  Suzanne Norris; Abdul Mohsen
Journal:  BMJ Clin Evid       Date:  2009-09-23

8.  Correlation between maternal hepatitis B surface antigen carrier status with social, medical and family factors in an endemic area: have we overlooked something?

Authors:  O K Chan; T T Lao; S S H Suen; T K Lau; T Y Leung
Journal:  Infection       Date:  2011-06-29       Impact factor: 3.553

9.  Epidemiology of hepatitis B virus infection in Albania.

Authors:  Bashkim Resuli; Skerdi Prifti; Bledar Kraja; Tatjana Nurka; Mimoza Basho; Edita Sadiku
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

10.  Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons.

Authors:  James W Keck; Lisa R Bulkow; Gregory A Raczniak; Susan E Negus; Carolyn L Zanis; Michael G Bruce; Philip R Spradling; Eyasu H Teshale; Brian J McMahon
Journal:  Clin Vaccine Immunol       Date:  2014-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.